Springworks Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
SpringWorks Therapeutics, Inc. has completed its acquisition by Merck KGaA for $47.00 per share in cash, leading to its delisting from The Nasdaq Stock Market.
SpringWorks Therapeutics, Inc. announced that its stockholders overwhelmingly approved the proposed merger agreement with Merck KGaA, Darmstadt, Germany, at a special meeting held on June 26, 2025.
SpringWorks Therapeutics, Inc. announced the satisfaction of critical antitrust conditions for its proposed merger with Merck KGaA, including the expiration of the HSR Act waiting period and Bundeskartellamt approval, moving closer to a second-half 2025 consummation.
SpringWorks Therapeutics held its annual meeting on May 14, 2025, electing directors, ratifying the appointment of Ernst & Young LLP as its independent auditor, and approving executive compensation.
8-K: Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion, Expanding Rare Tumor Portfolio
Merck KGaA, Darmstadt, Germany will acquire SpringWorks Therapeutics for $47 per share in cash, valuing the company at approximately $3.9 billion, to bolster its healthcare business and expand its presence in the rare tumor market.
SpringWorks Therapeutics announces positive Q4 and full year 2024 financial results, driven by OGSIVEO sales and the FDA approval of GOMEKLI.
SpringWorks Therapeutics' GOMEKLI (mirdametinib) has been approved by the FDA for treating adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
SpringWorks Therapeutics reports strong preliminary revenue for OGSIVEO and a solid cash position, projecting profitability by the first half of 2026.
SpringWorks Therapeutics announced positive third-quarter 2024 financial results, highlighted by strong OGSIVEO sales and progress in their pipeline, including priority review for mirdametinib.
SpringWorks Therapeutics announced $40.2 million in OGSIVEO net product revenue for Q2 2024 and significant progress in its clinical pipeline.
SpringWorks Therapeutics has appointed Dr. Martin Mackay, a seasoned R&D executive, to its Board of Directors, effective July 29, 2024.
SpringWorks Therapeutics has received notice of termination from GlaxoSmithKline (GSK) for their collaboration and license agreement, effective in 180 days.
SpringWorks Therapeutics held its annual meeting on May 16, 2024, electing a director, ratifying its auditor, and approving executive compensation on an advisory basis.
8-K: SpringWorks Therapeutics Reports $21 Million in First Quarter OGSIVEO Sales and Advances Pipeline
SpringWorks Therapeutics announced strong first quarter 2024 financial results, highlighted by $21 million in OGSIVEO net product revenue and progress in their clinical pipeline.
SpringWorks Therapeutics has entered into a sales agreement for an at-the-market offering of up to $250 million of its common stock.
SpringWorks Therapeutics announced its full year and fourth quarter 2023 financial results, highlighted by the launch of OGSIVEO and progress in its pipeline.
L. Mary Smith, Chief Development Officer of SpringWorks Therapeutics, has resigned due to family caretaking responsibilities but will transition to a Senior Strategic Advisor role.